

## **RaQualia Pharma and Velovia Pharma enter into an agreement to develop pet pharmaceuticals**

Nagoya and Nashville, April 3, 2024 - RaQualia Pharma Inc. (Headquarters: Nagoya, Aichi, Japan; President & CEO: Hirobumi Takeuchi; "RaQualia Pharma") and Velovia Pharma, LLC (Headquarters: Nashville, Tennessee, United States; CEO: David K. Rosen, DVM; "Velovia Pharma") have agreed to enter into an option and license agreement ("Agreement") for four compounds in RaQualia Pharma's development pipeline for use in animal health.

Under the terms of the Agreement, RaQualia Pharma and Velovia Pharma are entering into an exclusive option agreement to evaluate, develop, manufacture, and market veterinary medicines containing compounds which have potential applications in gastrointestinal, metabolic and fibrotic disease indications. The exclusive option is exercisable on a compound-by-compound basis. Velovia Pharma will pay RaQualia Pharma an option exercise fee upon exercise of an option for one or more of the compounds and RaQualia Pharma will be eligible to receive milestone payments as development progresses. In addition, RaQualia Pharma will receive sales royalties and milestones from Velovia Pharma based on product sales.

Hirobumi Takeuchi, President & CEO of RaQualia Pharma, stated: "I am very pleased that a new partnership with Velovia Pharma, led by Dr. David Rosen and his team, who have deep knowledge and experience in the development and commercialization of pet pharmaceuticals, has opened up the possibility of developing four of our development candidates for use in pet therapeutics. Dr. David Rosen is the founder of Aratana Therapeutics and has played a key role in the development of the veterinary medicines that originated with RaQualia Pharma. I sincerely hope these compounds will help the companion animals suffering from illness and their owners."

David Rosen, CEO of Velovia Pharma, stated: "I am very pleased to be able to partner once again with RaQualia Pharma to evaluate and potentially develop compounds from their portfolio. Velovia Pharma's mission is to develop novel medicines from the pharma industry and obtain regulatory approvals important to companion animal care. We have a long and successful history working together with RaQualia Pharma to bring innovative medicines to the animal health market and I look forward to the opportunity to work together again."

Through the Agreement, RaQualia Pharma and Velovia Pharma will further strengthen their development pipelines and contribute to improving the lives of pets and pet owners by providing new treatment options for pets.

### About RaQualia Pharma

RaQualia Pharma's mission is "We brighten people's lives through the power of innovation," and we strive to deliver new medications to those suffering from diseases where no effective treatment options exist or existing treatment methods are insufficient. Guided by this philosophy, we are dedicated to the research and development of new medications not only within our own company but also through establishing a next generation drug discovery value chain by strengthening partnerships with academia, start-ups, and venture companies. We, as professionals in drug discovery, are focusing on research and development efforts with a primary focus on patients. We pursue our science to create innovative, first-in-class therapeutic medications. For more information, please visit <https://www.raqualia.com/en/index.html>

About Velovia Pharma

Velovia Pharma is a animal health drug development company building a portfolio of novel, high-value prescription medicines for companion animals. Using a virtual business model, the Company will take drug development programs from pharma, biotech and academia and develop them into novel medicines through the FDA Center for Veterinary Medicine or other regulatory agencies, as necessary for approval. Velovia Pharma will commercialize the approved products through established global animal health companies